The rising incidence of cardiovascular diseases and technological 
advancements in interventional cardiology devices are the major factors 
that are driving the growth of the interventional cardiology devices market.
 Moreover, the emergence of bioabsorbable stents and the increasing 
healthcare expenditure in emerging countries are some of the other major
 factors that are expected to offer opportunities for market growth in 
the coming years.
According to research report the interventional
 cardiology devices market is expected to reach USD 20.85 billion by 
2022 from USD 14.52 billion in 2017, at a CAGR of 7.5%. 
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=548
•
 The angioplasty stents market is segmented into bare-metal stents, 
drug-eluting stents, and bioabsorbable stents. In 2017, drug-eluting 
stents dominated the angioplasty stents market as they provide better 
clinical outcomes as compared to bare-metal stents.
• The 
angioplasty balloons market is segmented into old/normal balloons, 
cutting & scoring balloons, and drug-eluting balloons. Although the 
old/normal balloons segment dominated this market in 2017, the 
drug-eluting balloons segment is estimated to grow at the highest CAGR 
during the forecast period.
• The other interventional cardiology
 devices market is further classified into guidewires, vascular closure 
devices, introducer sheaths, and balloon inflation devices. The vascular
 closure devices segment is estimated to grow at the highest rate during
 the forecast period. 
The interventional cardiology devices 
market is geographically segmented into North America, Europe, Asia 
Pacific, and the Rest of the World (RoW). Asia Pacific is expected to 
register the highest growth due to the improving healthcare 
infrastructure, the heavy burden of cardiovascular diseases, rising 
healthcare expenditure, and growth in the demand for interventional 
cardiology devices.
Get Report Sample: https://www.marketsandmarkets.com/requestsampleNew.asp?id=548 
The
 key players operating in the interventional cardiology devices market 
include Medtronic (US), Boston Scientific (US), Abbott Laboratories 
(US), Terumo (Japan), Cordis (US), B. Braun (Germany), C.R. Bard (US), 
Biosensors (Singapore), and Biotronik (Germany).